Cadrenal Therapeutics Advances CAD-1005 Toward Phase 3 Registration Trial After FDA End-of-Phase 2 Guidance

Following a completed End-of-Phase 2 meeting with FDA, Cadrenal Therapeutics is entering BIO International Convention 2026 with a defined registration path for CAD-1005, its selective 12-lipoxygenase (12-LOX) inhibitor under investigation for Heparin-Induced Thrombocytopenia (HIT). For regulatory affairs leads, the EOP2 outcome is the operative signal: FDA has provided guidance supporting a single pivotal Phase 3 trial, compressing the typical multi-study registration burden for this orphan indication.

CAD-1005 carries both Orphan Drug and Fast Track designations from FDA, positioning the program for expedited review and potential labeling exclusivity in a condition where no new therapies have been approved in over two decades. Phase 2 data indicated a reduction in thrombotic events in HIT patients. Unlike existing anticoagulant approaches that address thrombotic risk downstream, CAD-1005 is being investigated to interrupt the immune signaling feedback loop driving HIT pathophysiology, a mechanistic distinction that will bear directly on trial endpoint selection and the benefit-risk narrative submitted to the agency.

Beyond the lead asset, Cadrenal is using the BIO 2026 partnering forum to advance its broader 12-LOX inhibitor platform, designated CAD-2000, targeting chronic inflammatory conditions including atherosclerosis, microvascular thrombosis, diabetes, obesity, and oncology. Emerging research positions 12-LOX as a modulator of inflammatory signaling without the systemic immunosuppression associated with conventional anti-inflammatory agents, though clinical validation in these indications remains early-stage.

The company's second late-stage asset, tecarfarin, is an oral Vitamin K antagonist also carrying Orphan Drug and Fast Track designations for patients with End-Stage Renal Disease, Atrial Fibrillation, and those with implanted mechanical circulatory support devices including Left Ventricular Assist Devices. This population represents a segment where standard anticoagulation profiles are suboptimal, and where manufacturing and formulation consistency under 21 CFR Part 211 will be a key operational consideration as the program advances toward potential commercialization.

Cadrenal's executive team will host partnering meetings at the San Diego Convention Center from June 22–25, 2026, with discussions centered on development and commercialization opportunities across both programs.

The Phase 3 trial design parameters emerging from the EOP2 meeting will be the first measurable checkpoint for assessing whether Cadrenal's regulatory strategy translates into an approvable submission timeline.

Source: Cadrenal Therapeutics, Inc. via GlobeNewswire, June 3, 2026.